Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

SC Pharmaceuticals Inc (SCPH)

SC Pharmaceuticals Inc (SCPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 162,630
  • Shares Outstanding, K 50,040
  • Annual Sales, $ 13,590 K
  • Annual Income, $ -54,810 K
  • EBIT $ -64 M
  • EBITDA $ -64 M
  • 60-Month Beta 0.14
  • Price/Sales 11.78
  • Price/Cash Flow N/A
  • Price/Book 5.21

Options Overview Details

View History
  • Implied Volatility 253.04% ( +33.48%)
  • Historical Volatility 70.86%
  • IV Percentile 97%
  • IV Rank 76.03%
  • IV High 328.36% on 11/26/24
  • IV Low 14.11% on 06/20/24
  • Put/Call Vol Ratio 102.00
  • Today's Volume 103
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 5,291
  • Open Int (30-Day) 5,110

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.49
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +5.54%
on 12/16/24
3.82 -12.58%
on 11/27/24
-0.01 (-0.45%)
since 11/18/24
3-Month
3.08 +8.46%
on 11/15/24
5.63 -40.76%
on 09/19/24
-2.09 (-38.58%)
since 09/18/24
52-Week
3.08 +8.46%
on 11/15/24
6.71 -50.30%
on 12/22/23
-2.57 (-43.47%)
since 12/18/23

Most Recent Stories

More News
2 "Strong Buy"-Rated Biotech Stocks With 303% to 446% Upside Potential

While the upside is appealing, penny stocks carry some risks.

TCRX : 3.01 (+1.35%)
$SPX : 6,060.57 (+0.16%)
SCPH : 3.36 (+3.48%)
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

SCPH : 3.36 (+3.48%)
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

SCPH : 3.36 (+3.48%)
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

SCPH : 3.36 (+3.48%)
Pre-Market Brief: Stocks Rebound As Bond Yields Fall, China’s COVID Spike Remains In Focus

December S&P 500 futures (ESZ22) are trending up +0.23% this morning after three major US benchmark indices ended Monday roughly down as market participants remained cautious after reports suggested China...

ESZ22 : 3,871.47s (-0.66%)
ZM : 85.74 (+1.35%)
MULN : 1.3700 (+11.38%)
LYFT : 14.19 (+1.28%)
SYM : 25.26 (-1.06%)
A : 136.69 (+0.17%)
SCPH : 3.36 (+3.48%)
scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act target action date of October 8, 2022 Continued to advance...

SCPH : 3.36 (+3.48%)
scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

BURLINGTON, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and...

SCPH : 3.36 (+3.48%)
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints FUROSCIX demonstrated an acceptable...

SCPH : 3.36 (+3.48%)
scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients

Virtual event scheduled for Wednesday, July 13 at 10:00 AM EDT...

SCPH : 3.36 (+3.48%)
scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting

Oral and moderated poster presentations of FREEDOM-HF study to be presented...

SCPH : 3.36 (+3.48%)

Business Summary

scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company's pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via...

See More

Key Turning Points

3rd Resistance Point 3.60
2nd Resistance Point 3.49
1st Resistance Point 3.37
Last Price 3.36
1st Support Level 3.15
2nd Support Level 3.04
3rd Support Level 2.92

See More

52-Week High 6.71
Fibonacci 61.8% 5.32
Fibonacci 50% 4.89
Fibonacci 38.2% 4.46
Last Price 3.36
52-Week Low 3.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar